// App-Quantinova.ai

: The Frida Study: An Option for Mutated FLT3 Relapsed/Refractory Acute Myeloid Leukemia Patients with a Novel Iadademstat and Gilteritinib Combination Therapy

Researchers

Presenter

  • Amir T. Fathi

Principal Investigators

  • Mabel Arevalo

  • Sonia Gutierrez

  • Antonieta Molero

  • Natalia Sacilotto

  • Ana Limon

  • Douglas V Faller

Medical Centers

  • Oryzon Genomics, Cornella De Llobregat, Barcelona, ESP

  • Oryzon Genomics, Cornella de LLobregat, Spain

  • Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain

  • Oryzon Genomics SA, Boston, MA

  • Cancer Center, Massachusetts General Hospital, Boston, MA

Locations

  • Venezuela

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Peripheral blood mononuclear cell

  • Fms related tyrosine kinase 3

  • Lysine-specific histone demethylase 1A

Drug/Treatment

  • gilteritinib

  • Iadademstat

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Double Blind/Blinded

  • Tolerability

  • Controlled

  • Cohort

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved